- cafead   Jun 26, 2024 at 10:02: AM
via Sanofi has reported one-year follow-up findings from an ongoing Phase II clinical trial of its complement C1s inhibitor, riliprubart, in chronic inflammatory demyelinating polyneuropathy (CIDP) patients.
article source
article source